Author:
Strand Liam,Sandman Lars,Tinghög Gustav,Nedlund Ann-Charlotte
Abstract
Abstract
Background
When rationing health care, a commonly held view among ethicists is that there is no ethical difference between withdrawing or withholding medical treatments. In reality, this view does not generally seem to be supported by practicians nor in legislation practices, by for example adding a ‘grandfather clause’ when rejecting a new treatment for lacking cost-effectiveness. Due to this discrepancy, our objective was to explore physicians’ and patient organization representatives’ experiences- and perceptions of withdrawing and withholding treatments in rationing situations of relative scarcity.
Methods
Fourteen semi-structured interviews were conducted in Sweden with physicians and patient organization representatives, thematic analysis was used.
Results
Participants commonly express internally inconsistent views regarding if withdrawing or withholding medical treatments should be deemed as ethically equivalent. Participants express that in terms of patients’ need for treatment (e.g., the treatment’s effectiveness and the patient’s medical condition) withholding and withdrawing should be deemed ethically equivalent. However, in terms of prognostic differences, and the patient-physician relation and communication, there is a clear discrepancy which carry a moral significance and ultimately makes withdrawing psychologically difficult for both physicians and patients, and politically difficult for policy makers.
Conclusions
We conclude that the distinction between withdrawing and withholding treatment as unified concepts is a simplification of a more complex situation, where different factors related differently to these two concepts. Following this, possible policy solutions are discussed for how to resolve this experienced moral difference by practitioners and ease withdrawing treatments due to health care rationing. Such solutions could be to have agreements between the physician and patient about potential future treatment withdrawals, to evaluate the treatment’s effect, and to provide guidelines on a national level.
Funder
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Linköping University
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Health (social science),Issues, ethics and legal aspects
Reference37 articles.
1. Rotteveel AH, Reckers-Droog VT, Lambooij MS, De Wit GA, Van Exel NJA. Societal views in the Netherlands on active disinvestment of publicly funded healthcare interventions. Soc Sci Med. 2021;272:113708.
2. Daniels T, Williams I, Robinson S, Spence K. Tackling disinvestment in health care services. J Health Org Manag. 2013;27(6):762–80.
3. Elshaug AG, Hiller JE, Tunis SR, Moss JR. Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices. Aust N Z Health Policy. 2007;4(1):23.
4. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33(9):905–24.
5. National Institute for Health and Care Excellence. Ibrutinib for treating relapsed or refractory mantle cell lymphoma: National Institute for Health and Care Excellence; 2018. https://www.nice.org.uk/guidance/ta502/chapter/1-Recommendations.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献